Brief: Asit Biotech Announces Validation Of Its Patient Blood Cell In Vitro Selection Platform

European Medical Solutions SA

02/05/2018 06:35

May 2 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ANNOUNCES VALIDATION OF ITS PATIENT BLOOD CELL IN VITRO
SELECTION PLATFORM FOR ITS NEW PRODUCT CANDIDATES AND FILING OF
A EUROPEAN PATENT APPLICATION
    * DURING A FIRST PHASE III TRIAL DURING A FIRST PHASE III
TRIAL
(BTT009) CLINICAL EFFICACY OF GP-ASIT+ WAS STATISTICALLY
SIGNIFICANTLY CONFIRMED
    * EFFICACY WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAI
EFFICACY
WAS SUPPORTED BY IMMUNOLOGICAL RESULTS OBTAINED ON GROUP OF
PATIENTS TREATED AT GHENT UNIVERSITY HOSPITAL
    * SELECTION METHOD DEVELOPED BY ASIT BIOTECH HAS BEEN
CLAIMED IN A
PATENT APPLICATION FILED IN EUROPE ON 30 APRIL 2018
    * PATENT SAFEGUARDS ASIT BIOTECH'S FUTURE DEVELOPMENTS

Source text for Eikon:  ID:nBw9smZT3a 
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))